Safety and Immunogenicity of a Recombinant Two-Component SARS-CoV-2 Protein Vaccine: Randomized, Double-Blind, Placebo-Controlled Phase I and Phase II Studies.

Chris Wynne, Abundio Balgos,Jingxin Li, Paul Hamilton,Louie Tirador,Anjuli May Jaen,Chen Mo, Zijing Yue, Ying Ma, Qingshuang Wang, Rendu Wen, Zheng Yao,Jiaping Yu,Wenrong Yao, Jianhui Zhang,Hui Zheng,Kunxue Hong,Fengcai Zhu, Yong Liu

INFECTIOUS DISEASES AND THERAPY（2024）

Cited 0|Views30

Key words

SARS-CoV-2,Recombinant two-component SARS-CoV-2 protein vaccine,ReCOV,Omicron,Clinical trials

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined